BioCryst resumes flu trial
Executive Summary
BioCryst resumes enrollment in a 1,300-patient Phase III trial for its neuraminidase inhibitor peramivir after discussing additional monitoring with FDA; the trial was stopped in early 2001. Johnson & Johnson returned rights to the influenza drug to BioCryst at that time (1"The Pink Sheet" June 11, 2001, p. 19)...